Stock 688266 SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Stock

Equities

688266

CNE100003RP1

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
53.4 CNY +4.38% Intraday chart for Suzhou Zelgen Biopharmaceuticals Co.,Ltd. +15.78% +0.87%
04-19 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-12 Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials MT

Financials

Sales 2024 * 957M 132M 181M Sales 2025 * 1.69B 234M 319M Capitalization 14.14B 1.95B 2.67B
Net income 2024 * -151M -20.84M -28.49M Net income 2025 * 273M 37.68M 51.51M EV / Sales 2024 * 14.8 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 8.35 x
P/E ratio 2024 *
-92.9 x
P/E ratio 2025 *
51.8 x
Employees 843
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.97%
More Fundamentals * Assessed data

Chart Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Dynamic Chart

Latest news about Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug MT
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding CI
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug MT
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug MT
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China MT
More news

Quotes and Performance

1 day+4.38%
1 week+15.78%
Current month-0.93%
1 month+1.64%
3 months+21.53%
6 months+36.22%
Current year+0.87%
More quotes

Highs and lows

1 week
45.30
Extreme 45.3
53.75
1 month
45.30
Extreme 45.3
55.15
Current year
33.20
Extreme 33.2
55.48
1 year
33.20
Extreme 33.2
60.11
3 years
21.68
Extreme 21.68
85.00
5 years
21.68
Extreme 21.68
128.92
10 years
21.68
Extreme 21.68
128.92
More quotes

Managers and Directors - Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Managers TitleAgeSince
Hui Ping Lu FOU
 Founder 57 09-03-17
Ze Lin Sheng CEO
 Chief Executive Officer 64 09-03-17
Gang Huang DFI
 Director of Finance/CFO 53 18-12-31
Members of the board TitleAgeSince
Bing Hui Zhang BRD
 Director/Board Member 61 -
Fan Zhi Huang BRD
 Director/Board Member 57 22-05-18
Ze Lin Sheng CEO
 Chief Executive Officer 64 09-03-17
More insiders

ETFs positioned on Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Quotes

Date Price Change Volume
24-04-26 53.4 +4.38% 2,525,596
24-04-25 51.16 +0.51% 1,878,556
24-04-24 50.9 +2.33% 2,204,992
24-04-23 49.74 +5.58% 4,111,452
24-04-22 47.11 +2.15% 2,195,039

End-of-day quote Shanghai S.E., April 25, 2024

More quotes

Company Profile

Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing. The Company's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The Company operates in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
53.4 CNY
Average target price
64 CNY
Spread / Average Target
+19.85%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD. Stock Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
+0.87% 1.95B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688266 Stock